Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IKS014 in Advanced HER2+ Solid Tumors
NCT05872295Phase 1Recruiting
- Sponsor
- Iksuda Therapeutics
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of caxmotabart entudotin in breast cancer, gastric cancer (GC), gastroesophageal junction cancer and 1 more (6 arms), sponsored by Iksuda Therapeutics. Primary endpoints: Recommended Phase 2 Dose at 24 months and Objective Response Rate at 24 months. Started Sep 2023; status: recruiting.
02
Drugs
caxmotabart entudotin
03
Conditions
breast cancergastric cancer (GC)gastroesophageal junction cancersolid tumor
Beyond the preview
Go deeper on NCT05872295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05872295.